The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice

Elise Siegert¹, Friedemann Paul²,³, Michael Rothe⁴ and Karsten H. Weylandt¹,²*

Abstract

Background: There is a large body of experimental evidence suggesting that omega-3 (n-3) polyunsaturated fatty acids (PUFAs) are capable of modulating immune function. Some studies have shown that these PUFAs might have a beneficial effect in patients suffering from multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system (CNS). This could be due to increased n-3 PUFA-derived anti-inflammatory lipid mediators. In the present study we tested the effect of an endogenously increased n-3 PUFA status on cuprizone-induced CNS demyelination and remyelination in fat-1 mice versus their wild-type (wt) littermates.

Results: CNS lipid profiles in fat-1 mice showed a significant increase of eicosapentaenoic acid (EPA) levels but similar docosahexaenoic acid levels compared to wt littermates. This was also reflected in significantly higher levels of mono-hydroxy EPA metabolites such as 18-hydroxyeicosapentaenoic acid (18-HEPE) in fat-1 brain tissue. Feeding fat-1 mice and wt littermates 0.2% cuprizone for 5 weeks caused a similar degree of CNS demyelination in both groups; remyelination was increased in the fat-1 group after a recovery period of 2 weeks. However, at p = 0.07 this difference missed statistical significance.

Conclusions: These results indicate that n-3 PUFAs might have a role in promotion of remyelination after toxic injury to CNS oligodendrocytes. This might occur either via modulation of the immune system or via a direct effect on oligodendrocytes or neurons through EPA-derived lipid metabolites such as 18-HEPE.

Keywords: Multiple sclerosis, n-3 PUFAs, Lipid mediators, Inflammation, Oligodendrocytes, Remyelination

Background

Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS. In the Western world it is the main cause of disability in young adults [1] surpassed only by trauma, yet its etiology remains elusive. Recent research has acknowledged that even at its onset MS is a neurodegenerative disease with irreversible damage to axons and neurons [2, 3]. Although the precise mechanism responsible for neuronal loss is not known, the two main risk factors for injurious processes are inflammation and demyelination.

However, recent evidence suggests that the inflammatory response to demyelination is not just a risk factor for neuronal loss, but also a necessary condition for remyelination [4–6]. It has been shown that inflammation enhances remyelination via direct effects on oligodendrocyte precursor cells (OPCs) survival, migration and differentiation [7, 8]. Also, the presence of myelin debris in CNS tissue inhibits remyelination by OPCs [9, 10]. Hence the presence of activated macrophages that clear this debris is essential for remyelination. Furthermore, activated macrophages are also capable of inducing OPCs [11, 12]. This Janus-face of inflammation has resulted in the distinction between destructive and protective...
inflammation, where protective inflammation is associated with enhanced remyelination and reduced neuronal loss.

Despite promising initial results, all recently developed drugs that tried to address these new findings have been unable to stop disease progression or to exert neuroprotection or even neuroregeneration [13]. Instead, some of the newly developed drugs had adverse side effects [14, 15] or unexpected drug interactions [16]. There are some suggestions that diets which are high in n-3 PUFAs and low in saturated fatty acids might stabilize disease in MS patients [17, 18]. The rationale behind this approach is that n-3 PUFAs via their lipid mediators that are also known as resolvins and protectins [19], might modulate the destructive autoinflammatory response. However, empirical evidence supporting this advice is limited. In a Cochrane review of randomized trials of dietary interventions for MS, Farinotti et al. [20] could not find a significant effect of neither omega-6 (n-6) nor n-3 PUFAs on disease progression nor relapse rate. By contrast, a recent epidemiological study from Australia suggested that the risk for central nervous system demyelination is reduced in people with a higher intake of omega-3 PUFA [21].

There have been many studies in rodents looking at the anti-inflammatory effect of PUFAs in experimental autoimmune encephalomyelitis (EAE) as an animal model for MS [22–24]. However, in all these studies the focus was on n-6 PUFAs only. So far only one study [25] has used the cuprizone model for the study of the n-3 PUFA effect in neural demyelination and remyelination and found that a diet high in salmon fish oil protected from demyelination and increased remyelination [25].

We set out to confirm the results of this first n-3 PUFA cuprizone study in the fat-1 mouse model. This mouse, by expressing fat-1 n-3 PUFA desaturase from C. elegans, can endogenously synthesize n-3 PUFA from n-6 PUFA without using dietary supplementation [26] thus eliminating confounding factors of diet [27]. These mice were recently used in several models of neurological disease, such as Alzheimer’s disease [28], Parkinson’s disease [29], epilepsy [30] and stroke-related brain injury [31]. In all models, when compared to wt littermates, they were protected from neuronal damage. Using the fat-1 model, the cuprizone model of demyelination is superior to the EAE model, because in EAE the priming and proliferation of autoreactive T-cells might already be impeded by the differences in n-3 PUFA tissue status.

**Methods**

**Animals**

Transgenic fat-1 mice were engineered as previously described [26]. They were subsequently backcrossed onto a C57BL/6 background at least four times. Generations of female heterozygous fat-1 mice and male wt mice were then mated to obtain wt and transgenic mice from the same offspring. In this study, all transgenic fat-1 mice used were heterozygous. Animals were kept under specific pathogen-free conditions in standard cages and were maintained in an air-conditioned atmosphere with a controlled 12 h light–dark cycle. They were fed a special semi-purified diet (AIN-76A containing 10% corn oil) high in n-6 and low in n-3 fatty acids. Sterile drinking water was given ad libitum. Each cage housed four to six weight-matched female mice. Mouse studies were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care (Additional file 1: Figure S1).

Mice were divided into a fat-1 group and a wt group according to their phenotype. For phenotyping the tip of mouse-tails (100 mg) was cut off from six-week-old mice and subjected to gas chromatographic analysis. The ratio between n-6 PUFAs [arachidonic acid (AA) and gamma-linolenic acid (GLA n-6)] and n-3 [alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA n-3) and docosahexaenoic acid (DHA)] was determined for each individual mouse to distinguish between wt and transgenic phenotypes. Mice that had an n-6/n-3 ratio ≤10 were assigned to the wt group and those with an n-6/n-3 ratio >10 were assigned to the wt group. The analysis of the three most important PUFAs, AA, EPA and DHA, are presented in Fig. 1. The analysis of the three most important PUFAs, AA, EPA and DHA, are presented in Fig. 1.

Chemically induced demyelination with cuprizone

Six experimental groups were set up to investigate the impact of endogenously altered n-3/n-6 PUFA status on

![Fig. 1 Lipid profile in wt and fat-1 mouse-tails. Fatty acid composition of the tail was analysed using GC. The long-chain PUFAs AA, EPA and DHA were included in this comparison. The respective mean values and standard errors for wt animals are AA 31.9% (±0.6), EPA 9.5% (±0.6) and DHA 3.1% (±0.7). For fat-1 animals they are AA 3.5% (±0.7), EPA 9.5% (±0.6) and DHA 10.9% (±0.4). There were statistically significant differences between all three PUFAs in mouse-tails.](image-url)
remyelination following cuprizone-induced demyelination in mice (see Additional file 2: Figure S2 for details). Starting at nine weeks of age control animals (four fat-1 and four wt mice) were maintained on a normal pulverized diet for five weeks, while cuprizone animals received a pulverized diet containing 0.2% cuprizone (w/w) (Bis(cyclohexanone)oxalldihydrazone, Sigma-Aldrich, St. Louis, MO, USA), also for five weeks. Animals in the cuprizone demyelination group (seven fat-1 and five wt mice) were sacrificed at the end of these five weeks on the cuprizone diet and their tissue was used to assess whether there were any differences in demyelination between wt and fat-1 animals. Animals in the cuprizone remyelination group (seven fat-1 and five wt mice) were first fed the cuprizone diet for five weeks and were then allowed to recover for another two weeks on a normal diet. They were then sacrificed in order to see whether there were any differences in remyelination between wt and fat-1 animals. Animal weight was recorded throughout the entire experiment.

All animals were sacrificed by anaesthesia with isoflurane (IsoFlo ®, Abbott Laboratories, Abbott Park, Illinois, USA). Following their sacrifice, animals were transcardially perfused with ice-cold PBS. Brains and spinal cords were then excised and the brain was cut into three parts: the rostral 2/3 of the brain were prepared for histology; the occipital 1/3 and the cerebellum, as well as the spinal cord, were fresh-frozen and stored at −20 °C for gas chromatography (GC) analysis.

**Histology**

The rostral 2/3 of the brains were first fixated in 4% PFA (Arcos Organics, Fairlawn, NJ, USA) at 4 °C for 24 h and subsequently quenched in a sucrose gradient (Sigma-Aldrich, St. Louis, MO, USA) over two days before they were fresh-frozen in Shandon M-1 Embedding Matrix® (Thermo Fisher Scientific, Waltham, MA, USA) for cryosectioning. Coronal brain sections were cut at 10 µm thickness corresponding to slice 205 of the Harvard High Resolution Mouse Brain Atlas [32]. Sections were then air-dried and stored at −20 °C until further processing. Luxol Fast Blue staining was used to quantify myelin.

For Luxol Fast Blue (LFB) staining, sections were first hydrated in aqua bidest. Next, sections were rinsed in 70% ethanol and placed in 0.1% LFB (Solvent Blue 38®, Sigma-Aldrich, St. Louis, MO, USA) staining solution for 6 h at 60 °C. Following the 6 h of staining, sections were then rinsed in 95% ethanol, followed by aqua bidest. In the next step sections were postfixed in 1% lithium carbonate solution (Sigma-Aldrich, St. Louis, MO, USA) and subsequently rinsed in 70% ethanol and aqua bidest. This step was repeated until there was a clear differentiation between white and grey matter staining. Sections were then counterstained in 0.1% Cresyl Violet acetate solution (Sigma-Aldrich, St. Louis, MO, USA). Eventually, sections were rinsed in aqua bidest followed by 95 and 100% ethanol, then xylol and then they were coverslipped.

Stainings were evaluated with a LSM 5 Pascal confocal microscope (Carl Zeiss AG, Oberkochen, Germany). Of each brain a photo was taken of the corpus callosum at slice 205 of the mouse brain atlas. These photos were then analysed using ImageJ software by three blinded independent assessments. First, equal volumes (300,000 square pixels) of corpus callosum were selected. Within this volume the area that stained positive for myelin was then selected and the size of the myelinated area was recorded (Additional file 2: S2).

**Gas chromatography**

For PUFA analysis, brain or tail tissues frozen in liquid nitrogen were ground into powder in liquid nitrogen. The powder was subjected to extraction of total lipids and fatty acid methylation by heating them at 100 °C for 1 h in a solution containing 2.5 ml hexane and 2.5 ml 14% boron trifluoride in methanol. Once the samples had cooled down to room temperature they were vortexed. Next, 1 ml water was added to the solution. In order to ensure that the concentration between the aqueous and the lipophilic phase was in equilibrium the samples were shaken by hand for 4 min. The phases were then separated by centrifugation and the lipophilic hexane phase containing fatty acid methyl esters was removed and dried under nitrogen. The fatty acid methyl ester residues were redissolved in 50 µl hexane and transferred into an autosampler vial. They were then analysed by GC using a fully automated Hewlett Packard 5890 system equipped with a flame ionization detector. Peaks of resolved fatty acids were identified by comparison with a fatty acid standard and the area under those resolved peaks represented their relative concentrations. The size of the areas was measured using a Perkin Elmer M1 integrator.

**Liquid chromatography mass spectrometry/mass spectrometry (LC MS/MS)**

For analysis of monohydroxy lipid metabolites thirty milligrams ground and frozen brain tissue from wt (n = 7) and fat-1 (n = 4) mice was mixed with methanol and internal standard (LTB4-d4) and hydrolysed with 300 µl of 10 M sodium hydroxide for 30 min at 60 °C. The solution was neutralized with 60% acetic acid and pH was adjusted to 6.0 with sodium acetate buffer. A solid phase extraction was performed with an anion exchange column (Bond Elute Certify II, Agilent, Santa Clara, CA) as described previously [33]. For elution, an n-hexane:ethyl acetate extraction mixture 25:75 with 1% acetic acid was used. The eluate was evaporated on a heating block at
40 °C under a stream of nitrogen to obtain a solid residue. Residues were then dissolved in 70 μl acetonitrile. An Agilent 1200 high performance liquid chromatography (HPLC) system and a solvent system consisting of acetonitrile/0.1% formic acid in water was used. The gradient elution was started with 15% acetonitrile, this was increased within 10 min up to 90% and held for 10 min. The HPLC system was coupled with an Agilent 6410 Triplequad mass spectrometer with electrospray ionization source. Analysis of lipid mediators was performed using Multiple Reaction Monitoring in negative mode and converted into an electrical signal by an electron multiplier dynode. The resulting signals were identified and quantified with the help of previously analysed standards, all from Cayman Chemical (Ann Arbor, MI, USA). Results were then analysed using Agilent Technology's MassHunter Workstation Software Quantitative Analysis B.03.01 and Quantitative Analysis B.02.00.

Monohydroxy lipid metabolites analysed were those either enzymatically or non-enzymatically derived from the long-chain PUFAs AA, EPA and DHA. In particular, we focused on AA-derived 5-, 8-, 9-, 12- and 15-hydroxyeicosatetraenoic acid (HETE). Concerning n-3 PUFA-derived monohydroxy lipid mediators we focused on EPA-derived 5-, 8-, 9-, 12-, 15- and 18-hydroxyeicosapentaenoic acid (HEPE) and on DHA-derived 4-, 7-, 8-, 10-, 11-, 13-, 14-, 16-, 17- and 20-hydroxydocosahexaenoic acid (HDHA).

**Statistical analysis**

Statistical analysis of the results was performed in GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, USA) calculating the mean values of group sizes ± standard error of the mean (SEM) and using the Mann–Whitney U test. Statistical significance was set at a level of p < 0.05. Whenever asterisks are used to describe levels of statistical significance, * stands for 0.05 > p > 0.01, ** for 0.01 ≥ p ≥ 0.001 and *** for p < 0.001.

**Results**

GC was used to analyse the lipid profile of brain tissue from wt and fat-1 mice. While lipid profiles of mouse tails showed significant differences for the long-chain omega-3 PUFA AA, EPA and DHA (Fig. 1), these differences were significant only for EPA in brain tissue, which was detectable only in the fat-1 mice tested (Fig. 2a). This was also reflected in the amounts of monohydroxy lipid metabolites derived from AA, EPA and DHA: While amounts of AA-derived HETEs and DHA-derived HDHAs were not significantly different, levels of EPA-derived HEPEs were significantly higher (Fig. 2b).

More specifically, there were no significant differences for 8-/9-HETE, as well as 5-HETE, 12-HETE and 15-HETE, which are derived from 5-, 12-, or 15-lipoxigenase action (Fig. 3a). Similarly, differences for the corresponding DHA metabolites 4-/7-HDHA, 14-HDHA and 17-HDHA were not significantly different between wt and fat-1 animals (Fig. 3c). In contrast, while present only in much smaller amounts, the corresponding EPA derived metabolites were all significantly increased in fat-1 mice: Most notably high amounts of 18-HEPE were found (Fig. 3b).

Given that 18-HEPE is a pathway marker of anti-inflammatory and pro-resolution mediators such as resolvin E1 and E2 [19], and an anti-inflammatory compound itself [34], we hypothesized that the difference between omega-3 PUFA in wt and fat-1 mice—while only clearly discernible for EPA and its hydroxy metabolites—might lead to an anti-inflammatory and/or pro-resolution phenotype in the context of cerebral inflammation.

In the next step we thus evaluated the effect of cuprizone feeding in wt and fat-1 mice. Feeding mice cuprizone had a suppressive effect on their metabolism, leading to weight loss in wt and fat-1 mice (−11 and −13%, respectively). There was no significant difference between those two groups indicating that expression of the fat-1 gene and the changed n-3 PUFA tissue content in fat-1 mice did not interfere with the uptake and toxic metabolic effect of cuprizone in this study (Additional file 3: S3).

The cuprizone feeding model allows to study demyelination as well as remyelination by analysing representative brain slides either directly after cuprizone feeding or later in the recovery period. Mice were sacrificed at two time points to evaluate the effect of different n-3 PUFA status on demyelination and remyelination and Luxol Fast Blue (LFB) staining was used to quantify myelin (Fig. 4). The mean volumes that stained positive for myelin were quantified as described in “Methods” (see also Additional file 3: S3).

Next, the mean volume and the SEM were calculated for each treatment group (Fig. 5). For the control groups, there were no significant differences between wt animals and fat-1 animals (wt control: mean 274,257 pixels² (±4078), fat-1 control: mean 287,886 pixels² (±7219), p = 0.23). This was true also for the demyelination group where wt animals had a mean volume of myelin in their corpus callosum that was similar to the values observed in fat-1 animals (wt demyelination 104,459 pixels² (±14,398), fat-1 demyelination 121,534 pixels² (±18,059, p = 0.51). At the same time the cuprizone-treated groups had both significantly lower myelin staining values than the control groups (p < 0.001). In the remyelination phase there was a close miss of statistical significance between remyelinated wt animals with a lower mean volume in wt animals (156,414 ± 25,717) versus higher values in fat-1 animals (239,981 ± 24,764) (p = 0.07).
Fig. 2 Long-chain PUFAs and their metabolites in brain tissue of wt and fat-1 mice. a Fatty acid composition in brain tissue of wt and fat-1 mice were analysed using GC. The only significant difference in n-3 PUFAs in wt and fat-1 brain tissue was observed for EPA (EPA in wt cerebella 0 ± 0; EPA in fat-1 cerebella 34.6 ± 19.5; p = 0.003), which was detectable only in the fat-1 mice tested. AA and DHA levels in wt and fat-1 mice were wt: 2549 ± 203, 4769 ± 539; fat-1: 2418 ± 169, 4904 ± 398 respectively. b Lipid metabolite profiles in brain tissue of wt and fat-1 mice were analysed using LC MS/MS. Similarly, levels of EPA-derived total HEPEs were significantly higher in fat-1 animals. Levels of AA-derived HETEs and DHA-derived HDHAs levels were similar among wt and fat-1 animals.

Fig. 3 Comparison of lipid metabolite profiles in brain tissue of wt and fat-1 mice. a Levels of AA-derived HETEs were analysed using LC MS/MS. They were relatively similar among wt and fat-1 animals (presented as mean values and SEM). b The only significant difference in lipid metabolites between wt and fat-1 brain tissue was observed for EPA-derived monohydroxy metabolites. Levels of EPA-derived HEPEs were significantly higher in fat-1 animals with particularly high amounts of anti-inflammatory 18-HEPE. c Concerning DHA-derived HDHAs, levels were also relatively similar in the brain tissue of wt and fat-1 mice with no significant differences among any of the DHA-derived metabolites.
Discussion
Comparing the lipid profile of tails and brain between healthy wt and fat-1 mice, we found only small differences in the FA profiles between wt and fat-1 mouse brain tissue (Fig. 2a). A possible explanation for this difference is that in the CNS DHA might play such a crucial role, so that it is enriched here even in the context of low n-3 PUFA supplementation. This has been shown previously by Jeffrey et al. [35] for DHA in retinal cells. Since then it has been suggested that a similar principle might regulate trafficking of certain n-3 PUFAs to the brain [36]. In rats that are depleted of dietary n-3 PUFAs there is an increase in DHA synthesis from ALA in the liver [37, 38]. Hence one possible scenario would be that in DHA-depleted dietary states there is preferential trafficking of liver-derived DHA to the brain, amongst others through lipoprotein receptors [37].

While the total difference in DHA was small, there was, however, a significant difference of the amounts of EPA present, leading to increased amounts of potentially anti-inflammatory and anti-fibrotic 18-HEPE [39] in fat-1 brains. At the same time, levels of anti-inflammatory DHA metabolites, while much higher than the EPA metabolites, were unchanged between wt and fat-1 groups (Fig. 3).

In the cuprizone feeding model of demyelination damage in the brain there was no difference in the amount of demyelination between fat-1 and the wt animals, possibly reflecting the fact that additional n-3 PUFA synthesis in fat-1 mice was not able to confer an additional protective effect on top of the already high n-3 PUFA levels in wt brains. However, we saw improved remyelination in fat-1 mice; but this difference missed statistical significance at p = 0.07. Given our relatively small sample size with an average group size of 5 animals statistical significance might be reached by increasing case numbers. Thus the data presented here suggest that an increased n-3 PUFA tissue status might lead to a mild beneficial effect of n-3 PUFAs on in vivo CNS remyelination in mice.

Our data are only partially consistent with previous data on the effect of n-3 PUFA in the cuprizone model of demyelination. Torkildsen et al. [25] had tested the effect of diets with different compositions of PUFAs on de- and remyelination in C57/BL6 mice with cuprizone-induced demyelination. They found that mice receiving a salmon-based diet suffered less demyelination in response to cuprizone than those on a cod liver or soybean oil diet and saw no differences in the degree of remyelination. The three different diets that were tested in Torkildsen’s study differed in the lipid source of their 4% lipid content. One diet contained its lipids from salmon fillets with an unknown n-3 PUFA content, the other from cod liver oil (with approx. 24 g n-3 PUFAs/100 ml cod liver oil, of which 12 g DHA and 8 g EPA) and the third from soybean oil (with approx. 50 g linoleic acid/100 ml soybean oil). Mice were started on one of these diets at four weeks of age, i.e. 4 weeks prior to cuprizone feeding. However, this study lacked direct PUFA measurements in brain tissue.

An important point of our study is that we quantified actual differences in PUFA tissue status both in the tail and in the CNS. Interestingly, despite small differences in the FA profile of wt and fat-1 animal brains, we were
able to see differences in the degree of remyelination between these groups. One possibility that would explain this finding is that despite similar AA and DHA profiles in the brain, there might be differences in the EPA-derived lipid mediators that are produced in the course of cuprizone-induced de- and remyelination. In this study we only established baseline measurements of hydroxyl metabolites, in which there was no difference for the DHA-derived metabolites but significant differences for the EPA-derived 18-HEPE.

Our finding of increased levels of EPA-derived 18-HEPE in the brain of fat-1 versus wt mice could be interpreted in the light of other recent studies of 18-HEPE. Endo et al. [40] showed that in fat-1 mice there is a selective enrichment of EPA in fat-1 transgenic bone marrow cells and EPA-metabolite 18-HEPE in fat-1 transgenic macrophages. Bone marrow transplantation experiments revealed that an 18-HEPE-rich environment through transplantation of fat-1 transgenic bone marrow prevented macrophage-mediated cardiac remodeling via cardiac fibroblasts. This anti-fibrotic effect of 18-HEPE on cardiac fibroblasts was reproduced in vivo and in vitro. Similarly, in a study on murine macrophages 18-HEPE was able to significantly decrease macrophages’ TNF-alpha formation in vitro [33].

While there might be a tight regulation of DHA levels in the CNS, differences in EPA levels might thus lead to significant changes in anti-inflammatory lipid metabolites in the brain. Therefore, a possible explanation for the protective effect of an n-3 PUFA-enriched tissue status in CNS demyelinating disease could be a difference particularly in EPA-derived metabolites such as 18-HEPE. Based on the data from Torkildsen et al. [25], these could affect mainly macrophage function, although further experiments might be necessary to assess also the role of astrocytes in this model. Future studies will now have to assess the activity and function of macrophages/microglia found at the sites of CNS injury in the cuprizone model and to understand the effect of EPA on activity of these cells.

As compared to our analysis in mice, a meta-analysis by Farinotti et al. [20] has concluded that n-3 PUFAs did not have an effect on 292 patients with relapsing remitting MS. However, there are several arguments why a positive effect of n-3 PUFAs on remyelination in patients suffering from MS might not have shown up in the two studies that were evaluated by Farinotti and colleagues [13, 41]: Patients in both studies received EPA at 1.71 and 1.98 g/d and DHA at 1.14 and 1.32 g/d, (which is well above the general dietary recommendations by most nutritional guidelines). Both studies found that there was a rise in EPA serum level in patients receiving fish oil compared to olive oil. While Weinstock-Guttman et al. [41] in their 1-year study found that EPA levels at 6 and 9 months correlated with disability at 12 months, Bates et al. [13] found a non-significant trend between higher EPA and DHA levels due to fish oil supplements and lower disability in MS patients following two years of dietary intervention. Only Bates et al. [13] checked for effective uptake of PUFAs into adipose tissue. While there was a significant increase in EPA and DHA in adipose tissue as early as 6 months after supplementation, most of the change was only seen at 2 years on therapeutic intervention. Hence, it would be essential in any interventional study to check for effective uptake of n-3 PUFAs into relevant tissue and to choose an appropriate time frame accordingly. The data from Bates et al. [13] suggests that the time frame that was chosen in those studies might have been too short. Also, it is necessary to define what the relevant tissue is, i.e. whether differences in lipid profiles in the CNS, in adipose tissue or in immune cells confer those potential benefits. Next, a recent epidemiological study from Australia with 267 cases and 517 controls showed a reduced risk of CNS demyelination with higher intake of omega-3 PUFA [21]. Furthermore, there is the possibility that isolated n-3 PUFA supplementation might not exert the same benefit as n-3 PUFAs derived from natural nutrition. The data from Torkildsen et al. suggests that salmon-derived n-3 PUFA might be superior to cod-liver oil [24]. Given these limitations, and as concluded by Farinotti et al. [20], future studies will be necessary to settle the question of an n-3 PUFA effect in MS. This underscores that the topic of n-3 PUFA supplementation in MS warrants further investigation.

Given that our observation of increased remyelination due to increased n-3 PUFA tissue content narrowly missed significance, future mouse studies are
also warranted to further establish this effect in a larger cohort of mice in the cuprizone model, as well as in other experimental MS models such as EAE.

**Conclusion**

In the present study using *fat-1* mice endogenously forming n-3 PUFAs we found a trend towards increased CNS remyelination after cuprizone damage in the context of higher EPA levels in the brain. The differences in remyelination—in the face of CNS lipid profiles differing only in EPA levels and not in DHA levels—might be due to EPA-derived metabolites such as 18-HEPE, for which anti-inflammatory and anti-fibrotic effects have been described. While DHA is more abundant in the CNS, this finding puts emphasis on the possible role of EPA and its metabolites in CNS remyelination.

**Additional files**

**Additional file 1: Figure S1.** Experimental groups. In order to assess the impact of n-3 versus n-6 PUFAs on de- and remyelination, animals were divided into six experimental groups. Ten wt and twelve fat-1 animals were fed on a 0.2 % cuprizone diet for five weeks, while four wt and four fat-1 animals were fed a normal diet instead. At the end of the five weeks both control groups and the five wt and six fat-1 animals that had been fed cuprizone were sacrificed. The remaining animals were allowed to recover for another two weeks on a normal diet before they, too, were sacrificed.

**Additional file 2: Figure S2.** Quantitative analysis of histological stainings. Representative areas of the corpus callosum were marked and measured using ImageJ software. The image was cropped such that the remaining corpus callosum measured 300,000 square pixels. Within the cropped image the myelinated area was then marked and measured using ImageJ again. Values were transferred into Excel for statistical analysis.

**Additional file 3: Figure S3.** Changes of animal weight in the course of the cuprizone treatment: There are clear differences in the development of animal weight between those animals that had received the cuprizone diet and those that had stayed on a normal diet. However, no significant difference could be found between wt and fat-1 animals that belong to the same treatment group.

**Additional file 4.** Data generated or analysed during this study are included in Additional file 1.

**Authors’ contributions**

ES and KW participated in the design of the study. ES and KW conceived the study and carried out the animal experiments, histology and participated in the lipid analyses. MR performed the LC–MS/MS analysis. ES, KW and FP contributed to the drafting and revision of the manuscript. All authors read and approved the final manuscript.

**Author details**

1 Division of Gastroenterology and Hepatology, Department of Medicine, Charité – Universitätsmedizin Berlin, Campus Virchow Hospital, Augustenburger Platz 1, 13353 Berlin, Germany. 2 Experimental and Clinical Research Center, Charité – Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Lindenberger Weg 80, 13125 Berlin, Germany. 3 NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. 4 Lipidomix GmbH, Robert-Rösle-Str. 10, 13125 Berlin, Germany.

**Acknowledgements**

We would like to thank Jing X. Kang for providing the *fat-1* mice, supporting the mouse experiments at Massachusetts General Hospital and assisting with advice to the study.

**Competing interests**

All authors declare no competing interests.

**Availability of data and material**

All data generated or analysed during this study are included in this published article and its Additional file 4.

**Ethics approval and consent to participate**

All mouse procedures in this study were reviewed and approved by the Massachusetts General Hospital Subcommittee on Research Animal Care.

**Funding**

The study was supported by Charité intramural research funding to KHW.

**Received:** 7 May 2016  **Accepted:** 22 November 2016  **Published online:** 24 January 2017

**References**

1. WHO. Atlas: multiple sclerosis resources in the world 2008. Geneva: World Health Organisation, Multiple Sclerosis International Foundation; 2008.
2. Sinnecker T, Mittelstaedt P, Dorr J, Pfeuller CF, Hamms L, Niendorf T, Paul F, Wuerfel J. Multiple sclerosis lesions and irreversibile brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study. Arch Neurol. 2012;69(6):739–45.
3. Oberwahrenbrock T, Ringelstein M, Jentschke S, Deuschke S, Deuschke K, Blombäck M, Bellmann-Strobl J, Hamel J, Ruprecht K, Schippling S, Hartung HP, et al. Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler. 2013;19(14):1887–95.
4. Rapalino O, Lazarov-Spiegler O, Agrawal E, Velan GJ, Yoles E, Fraidakis M, Solomon A, Gepstein R, Katz A, Belkin M, et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med. 1998;4(7):814–21.
5. Moalem G, Leibowitz-Abitt R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 1999;5(1):49–55.
6. Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H. BDNF and gp145 trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain. 2002;125(Pt 1):75–85.
7. Tourbath A, Linnington C, Bachelin C, Avellana-Adalid W, Wekerle H, Baron-Verhoeven A. Inflammation promotes survival and migration of the CGA oligodendrocyte progenitors transplanted in the spinal cord of both inflammatory and demyelinated EAE rats. J Neurosci Res. 1997;50(5):853–61.
8. Setzu A, Latha JD, Zhao C, Wells K, Rao MS, Ffrench-Constant C, Franklin RJ. Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. Glia. 2006;54(4):297–303.
9. Robinson S, Miller RH. Contact with central nervous system myelin inhibits oligodendrocyte progenitor maturation. Dev Biol. 1999;216(1):359–68.
10. Kotter MR, Li WW, Zhao C, Franklin RJ. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci Off J Soc Neurosci. 2006;26(1):329–32.
11. Glezner I, Lapointe A, Rivest S. Intranate immunity triggers oligodendrocyte progenitor reactvity and confines damages to brain injuries. FASEB J. 2006;20(6):750–2.
12. Rhodes KE, Raivich G, Fawcett JW. The injury response of oligodendrocyte precursor cells is induced by platelets, macrophages and inflammation-associated cytokines. Neuroscience. 2006;140(1):87–100.
13. Bates D, Cartledge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, Smith S, Woo E, Hawkins SA, Millar JH, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989;52(1):18–22.
14. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov. 2005;4(6):510–8.
15. Dorr J, Bitsch A, Schmalzl KJ, Chan A, von Ahsen N, Hummel M, Varon R, Lill CM, Vogel HP, Zipp F, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology. 2009;72(12):991–3.
16. Bimbbaum G, Cree B, Altafullah I, Zinsner M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390–5.
17. Millar JH, Zilkha KJ, Langman MJ, Wight HP, Smith AD, Belin J, Thompson RH. Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. Br Med J. 1973;1(5856):765–6.
18. Bowling AC. Complementary and alternative medicine and multiple sclerosis. Neurol Clin. 2011;29(2):465–80.
19. Kang JX, Weylandt KH. Modulation of inflammatory cytokines by omega-3 fatty acids. Sub-cell Biochem. 2008;49:133–43.
20. Fannotti M, Vacchi L, Simi S, Di Pietranzon C, Brait L, Filippini G. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 2012;12.Cd004192.
21. Hoare S, Lithander F, van der Mei J, Ponsonby AL, Lucas R. Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: Results from the Ausimmune Study. Mult Scler. 2016;22(7):884–92.
22. Mertin J, Stackpoole A. Suppression by essential fatty acids of experimental allergic encephalomyelitis is abolished by indomethacin. Prostaglandins Med. 1978;14(1):283–91.
23. Mertin J, Stackpoole A. The spleen is required for the suppression of experimental allergic encephalomyelitis by prostaglandin precursors. Clin Exp Immunol. 1979;36(3):449–55.
24. Hartlage LS, Layward L, Morris-Dowmes MM, Dumonde DC, Amor S. The protective effects of omega-6 fatty acids in experimental autoimmune encephalomyelitis (EAE) in relation to transforming growth factor-beta 1 (TGF-beta1) up-regulation and increased prostaglandin E2 (PGE2) production. Clin Exp Immunol. 2000;122(3):445–52.
25. Torkildsen O, Brunborg LA, Thorsen F, Mork SJ, Stangel M, Myhr KM, Bo L. Effects of dietary intervention on MR activity, de- and remyelination in the cuprizone model for demyelination. Exp Neurol. 2009;215(1):160–6.
26. Kang JX, Wang J, Wu L, Kang ZB. Transgenic mice: fat-1 mice convert n-6 fatty acids to n-3 fatty acids. Nature. 2004;427(6974):504.
27. Kang JX, Huot PSP, Reza-Lopez S, Prayittino NR, Kang JX, Burnham WM, Ma DWL. Seizure resistance in fat-1 transgenic mice endogenously synthesizing high levels of omega-3 polyunsaturated fatty acids. J Neurochem. 2008;105(2):380–8.
28. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390–5.
29. Taha AV, Huot PSP, Reza-Lopez S, Prayittino NR, Kang JX, Burnham WM, Ma DWL. Seizure resistance in fat-1 transgenic mice endogenously synthesizing high levels of omega-3 polyunsaturated fatty acids. J Neurochem. 2008;105(2):380–8.
30. Hu X, Zang F, Leak RK, Zhang W, Iwai M, Stetler RA, Dai Y, Zhao A, Gao Y, Chen J. Transgenic overproduction of omega-3 polyunsaturated fatty acids provides neuroprotection and enhances endogenous neurogenesis after stroke. Curr Mol Med. 2013;13(9):1465–73.
31. Hoare S, Lithander F, van der Mei J, Ponsonby AL, Lucas R. Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: Results from the Ausimmune Study. Mult Scler. 2016;22(7):884–92.
32. Mertin J, Stackpoole A. Suppression by essential fatty acids of experimental allergic encephalomyelitis is abolished by indomethacin. Prostaglandins Med. 1978;14(1):283–91.
33. Weylandt KH, Krause LF, Gomolka B, Chiu CY, Bilal S, Nadelory A, Waechter SF, Fischer A, Rothe M, Kang JX. Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-alpha. Carcinogenesis. 2011;32(6):897–903.
34. Endo J, Arita M. Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. J Cardiol. 2016;67(1):22–27.
35. Jeffrey BG, Weisberger HS, Neuringer M, Mitchell DC. The role of docosahexaenoic acid in retinal function. Lipids. 2001;36(9):859–71.
36. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015;7:52.
37. Scott BL, Bazan NG. Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc Natl Acad Sci. 1989;86(8):2903–7.
38. Igarashi M, DeMar JC, Ma K, Chang L, Bell JM, Rapoport SL. Docosahexaenoic acid synthesis from α-linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation. J Lipid Res. 2007;48(5):1150–8.
39. Krishnamurthy VR, Dougherty A, Haller CA, Chakof EL. Total synthesis and bioactivity of 18(R)-hydroxyeicosapentaenoic acid. J Org Chem. 2011;76(13):5433–7.
40. Endo J, Sano M, Itoke Y, Fukuda K, Kang JX, Arat J, Arita M. 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodelling. J Exp Med. 2014;211(8):1673–87.
41. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher and we will help you at every step:
14. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher
and we will help you at every step:
14. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher